nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CYP2C19—Gefitinib—lung cancer	0.0668	0.508	CbGbCtD
Methsuximide—CYP2C19—Teniposide—lung cancer	0.0648	0.492	CbGbCtD
Methsuximide—Antipyrine—CYP2A6—lung cancer	0.00236	0.17	CrCbGaD
Methsuximide—Phenobarbital—ABCC3—lung cancer	0.00212	0.153	CrCbGaD
Methsuximide—Leukopenia—Topotecan—lung cancer	0.00174	0.00396	CcSEcCtD
Methsuximide—Nausea—Crizotinib—lung cancer	0.00172	0.00391	CcSEcCtD
Methsuximide—Urticaria—Teniposide—lung cancer	0.0017	0.00387	CcSEcCtD
Methsuximide—Pancytopenia—Cisplatin—lung cancer	0.00169	0.00386	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Gemcitabine—lung cancer	0.00169	0.00385	CcSEcCtD
Methsuximide—Abdominal pain—Teniposide—lung cancer	0.00169	0.00385	CcSEcCtD
Methsuximide—Vomiting—Pemetrexed—lung cancer	0.00168	0.00382	CcSEcCtD
Methsuximide—Antipyrine—CYP2E1—lung cancer	0.00168	0.121	CrCbGaD
Methsuximide—Vomiting—Gefitinib—lung cancer	0.00167	0.0038	CcSEcCtD
Methsuximide—Rash—Pemetrexed—lung cancer	0.00166	0.00379	CcSEcCtD
Methsuximide—Dermatitis—Pemetrexed—lung cancer	0.00166	0.00379	CcSEcCtD
Methsuximide—Rash—Gefitinib—lung cancer	0.00165	0.00376	CcSEcCtD
Methsuximide—Dermatitis—Gefitinib—lung cancer	0.00165	0.00376	CcSEcCtD
Methsuximide—Haematuria—Gemcitabine—lung cancer	0.00163	0.00371	CcSEcCtD
Methsuximide—Nausea—Pemetrexed—lung cancer	0.00157	0.00357	CcSEcCtD
Methsuximide—Nausea—Gefitinib—lung cancer	0.00156	0.00355	CcSEcCtD
Methsuximide—Anorexia—Vinblastine—lung cancer	0.00155	0.00354	CcSEcCtD
Methsuximide—Pancytopenia—Etoposide—lung cancer	0.00155	0.00354	CcSEcCtD
Methsuximide—Pancytopenia—Paclitaxel—lung cancer	0.00152	0.00347	CcSEcCtD
Methsuximide—Anorexia—Topotecan—lung cancer	0.00151	0.00344	CcSEcCtD
Methsuximide—Anorexia—Erlotinib—lung cancer	0.00149	0.0034	CcSEcCtD
Methsuximide—Leukopenia—Vinorelbine—lung cancer	0.00149	0.00338	CcSEcCtD
Methsuximide—Ataxia—Docetaxel—lung cancer	0.00148	0.00337	CcSEcCtD
Methsuximide—Diarrhoea—Teniposide—lung cancer	0.00146	0.00333	CcSEcCtD
Methsuximide—Weight decreased—Paclitaxel—lung cancer	0.00145	0.0033	CcSEcCtD
Methsuximide—Erythema multiforme—Gemcitabine—lung cancer	0.00145	0.0033	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Etoposide—lung cancer	0.00145	0.00329	CcSEcCtD
Methsuximide—Insomnia—Erlotinib—lung cancer	0.00142	0.00323	CcSEcCtD
Methsuximide—Decreased appetite—Vinblastine—lung cancer	0.00142	0.00323	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Paclitaxel—lung cancer	0.00142	0.00323	CcSEcCtD
Methsuximide—Constipation—Vinblastine—lung cancer	0.00139	0.00318	CcSEcCtD
Methsuximide—Decreased appetite—Topotecan—lung cancer	0.00138	0.00314	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Topotecan—lung cancer	0.00137	0.00311	CcSEcCtD
Methsuximide—Haematuria—Paclitaxel—lung cancer	0.00136	0.0031	CcSEcCtD
Methsuximide—Decreased appetite—Erlotinib—lung cancer	0.00136	0.0031	CcSEcCtD
Methsuximide—Vomiting—Teniposide—lung cancer	0.00136	0.00309	CcSEcCtD
Methsuximide—Constipation—Topotecan—lung cancer	0.00135	0.00308	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Erlotinib—lung cancer	0.00135	0.00308	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—lung cancer	0.00135	0.00308	CcSEcCtD
Methsuximide—Rash—Teniposide—lung cancer	0.00135	0.00307	CcSEcCtD
Methsuximide—Dermatitis—Teniposide—lung cancer	0.00135	0.00307	CcSEcCtD
Methsuximide—Feeling abnormal—Vinblastine—lung cancer	0.00134	0.00306	CcSEcCtD
Methsuximide—Constipation—Erlotinib—lung cancer	0.00134	0.00305	CcSEcCtD
Methsuximide—Headache—Teniposide—lung cancer	0.00134	0.00305	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vinblastine—lung cancer	0.00133	0.00304	CcSEcCtD
Methsuximide—Feeling abnormal—Topotecan—lung cancer	0.00131	0.00297	CcSEcCtD
Methsuximide—Gastrointestinal pain—Topotecan—lung cancer	0.0013	0.00295	CcSEcCtD
Methsuximide—Anorexia—Vinorelbine—lung cancer	0.00129	0.00294	CcSEcCtD
Methsuximide—Pancytopenia—Docetaxel—lung cancer	0.00129	0.00294	CcSEcCtD
Methsuximide—Abdominal pain—Vinblastine—lung cancer	0.00129	0.00294	CcSEcCtD
Methsuximide—Gastrointestinal pain—Erlotinib—lung cancer	0.00128	0.00292	CcSEcCtD
Methsuximide—Nausea—Teniposide—lung cancer	0.00127	0.00289	CcSEcCtD
Methsuximide—Urticaria—Topotecan—lung cancer	0.00126	0.00287	CcSEcCtD
Methsuximide—Abdominal pain—Topotecan—lung cancer	0.00125	0.00285	CcSEcCtD
Methsuximide—Abdominal pain—Erlotinib—lung cancer	0.00124	0.00282	CcSEcCtD
Methsuximide—Erythema multiforme—Etoposide—lung cancer	0.00124	0.00282	CcSEcCtD
Methsuximide—Weight decreased—Docetaxel—lung cancer	0.00123	0.0028	CcSEcCtD
Methsuximide—Leukopenia—Irinotecan—lung cancer	0.00123	0.00279	CcSEcCtD
Methsuximide—Erythema multiforme—Paclitaxel—lung cancer	0.00121	0.00276	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Docetaxel—lung cancer	0.0012	0.00273	CcSEcCtD
Methsuximide—Leukopenia—Gemcitabine—lung cancer	0.00119	0.00272	CcSEcCtD
Methsuximide—Decreased appetite—Vinorelbine—lung cancer	0.00118	0.00268	CcSEcCtD
Methsuximide—Vision blurred—Cisplatin—lung cancer	0.00117	0.00267	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00117	0.00266	CcSEcCtD
Methsuximide—Constipation—Vinorelbine—lung cancer	0.00116	0.00264	CcSEcCtD
Methsuximide—Phenobarbital—CYP2A6—lung cancer	0.00115	0.0831	CrCbGaD
Methsuximide—Confusional state—Irinotecan—lung cancer	0.00113	0.00257	CcSEcCtD
Methsuximide—Feeling abnormal—Vinorelbine—lung cancer	0.00112	0.00254	CcSEcCtD
Methsuximide—Diarrhoea—Vinblastine—lung cancer	0.00112	0.00254	CcSEcCtD
Methsuximide—Leukopenia—Cisplatin—lung cancer	0.00111	0.00253	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vinorelbine—lung cancer	0.00111	0.00252	CcSEcCtD
Methsuximide—Tension—Paclitaxel—lung cancer	0.0011	0.0025	CcSEcCtD
Methsuximide—Nervousness—Paclitaxel—lung cancer	0.00108	0.00247	CcSEcCtD
Methsuximide—Diarrhoea—Topotecan—lung cancer	0.00108	0.00247	CcSEcCtD
Methsuximide—Irritability—Methotrexate—lung cancer	0.00108	0.00246	CcSEcCtD
Methsuximide—Dizziness—Vinblastine—lung cancer	0.00108	0.00246	CcSEcCtD
Methsuximide—Urticaria—Vinorelbine—lung cancer	0.00108	0.00245	CcSEcCtD
Methsuximide—Diarrhoea—Erlotinib—lung cancer	0.00107	0.00244	CcSEcCtD
Methsuximide—Abdominal pain—Vinorelbine—lung cancer	0.00107	0.00244	CcSEcCtD
Methsuximide—Anorexia—Irinotecan—lung cancer	0.00107	0.00243	CcSEcCtD
Methsuximide—Ataxia—Methotrexate—lung cancer	0.00107	0.00243	CcSEcCtD
Methsuximide—Vision blurred—Paclitaxel—lung cancer	0.00105	0.0024	CcSEcCtD
Methsuximide—Dizziness—Topotecan—lung cancer	0.00105	0.00239	CcSEcCtD
Methsuximide—Anorexia—Gemcitabine—lung cancer	0.00104	0.00236	CcSEcCtD
Methsuximide—Vomiting—Vinblastine—lung cancer	0.00104	0.00236	CcSEcCtD
Methsuximide—Dizziness—Erlotinib—lung cancer	0.00104	0.00236	CcSEcCtD
Methsuximide—Antipyrine—PTGS2—lung cancer	0.00103	0.0745	CrCbGaD
Methsuximide—Erythema multiforme—Docetaxel—lung cancer	0.00103	0.00234	CcSEcCtD
Methsuximide—Headache—Vinblastine—lung cancer	0.00102	0.00233	CcSEcCtD
Methsuximide—Leukopenia—Etoposide—lung cancer	0.00102	0.00232	CcSEcCtD
Methsuximide—Insomnia—Irinotecan—lung cancer	0.00101	0.0023	CcSEcCtD
Methsuximide—Vomiting—Topotecan—lung cancer	0.00101	0.00229	CcSEcCtD
Methsuximide—Leukopenia—Paclitaxel—lung cancer	0.001	0.00228	CcSEcCtD
Methsuximide—Rash—Topotecan—lung cancer	0.000999	0.00227	CcSEcCtD
Methsuximide—Dermatitis—Topotecan—lung cancer	0.000998	0.00227	CcSEcCtD
Methsuximide—Vomiting—Erlotinib—lung cancer	0.000997	0.00227	CcSEcCtD
Methsuximide—Somnolence—Irinotecan—lung cancer	0.000994	0.00226	CcSEcCtD
Methsuximide—Headache—Topotecan—lung cancer	0.000993	0.00226	CcSEcCtD
Methsuximide—Rash—Erlotinib—lung cancer	0.000988	0.00225	CcSEcCtD
Methsuximide—Dermatitis—Erlotinib—lung cancer	0.000988	0.00225	CcSEcCtD
Methsuximide—Insomnia—Gemcitabine—lung cancer	0.000985	0.00224	CcSEcCtD
Methsuximide—Headache—Erlotinib—lung cancer	0.000982	0.00224	CcSEcCtD
Methsuximide—Decreased appetite—Irinotecan—lung cancer	0.000972	0.00221	CcSEcCtD
Methsuximide—Eosinophilia—Methotrexate—lung cancer	0.00097	0.00221	CcSEcCtD
Methsuximide—Nausea—Vinblastine—lung cancer	0.000969	0.00221	CcSEcCtD
Methsuximide—Somnolence—Gemcitabine—lung cancer	0.000968	0.0022	CcSEcCtD
Methsuximide—Anorexia—Cisplatin—lung cancer	0.000967	0.0022	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Irinotecan—lung cancer	0.000965	0.0022	CcSEcCtD
Methsuximide—Constipation—Irinotecan—lung cancer	0.000956	0.00218	CcSEcCtD
Methsuximide—Decreased appetite—Gemcitabine—lung cancer	0.000947	0.00216	CcSEcCtD
Methsuximide—Nausea—Topotecan—lung cancer	0.000941	0.00214	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00094	0.00214	CcSEcCtD
Methsuximide—Confusional state—Etoposide—lung cancer	0.000938	0.00213	CcSEcCtD
Methsuximide—Constipation—Gemcitabine—lung cancer	0.000931	0.00212	CcSEcCtD
Methsuximide—Nausea—Erlotinib—lung cancer	0.000931	0.00212	CcSEcCtD
Methsuximide—Pancytopenia—Methotrexate—lung cancer	0.00093	0.00212	CcSEcCtD
Methsuximide—Diarrhoea—Vinorelbine—lung cancer	0.000927	0.00211	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—lung cancer	0.000923	0.0021	CcSEcCtD
Methsuximide—Feeling abnormal—Irinotecan—lung cancer	0.000921	0.0021	CcSEcCtD
Methsuximide—Confusional state—Paclitaxel—lung cancer	0.000919	0.00209	CcSEcCtD
Methsuximide—Gastrointestinal pain—Irinotecan—lung cancer	0.000914	0.00208	CcSEcCtD
Methsuximide—Feeling abnormal—Gemcitabine—lung cancer	0.000897	0.00204	CcSEcCtD
Methsuximide—Dizziness—Vinorelbine—lung cancer	0.000896	0.00204	CcSEcCtD
Methsuximide—Anorexia—Etoposide—lung cancer	0.000886	0.00202	CcSEcCtD
Methsuximide—Abdominal pain—Irinotecan—lung cancer	0.000884	0.00201	CcSEcCtD
Methsuximide—Decreased appetite—Cisplatin—lung cancer	0.000882	0.00201	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Cisplatin—lung cancer	0.000876	0.00199	CcSEcCtD
Methsuximide—Drowsiness—Methotrexate—lung cancer	0.000873	0.00199	CcSEcCtD
Methsuximide—Anorexia—Paclitaxel—lung cancer	0.000869	0.00198	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Methotrexate—lung cancer	0.000866	0.00197	CcSEcCtD
Methsuximide—Vomiting—Vinorelbine—lung cancer	0.000862	0.00196	CcSEcCtD
Methsuximide—Rash—Vinorelbine—lung cancer	0.000855	0.00195	CcSEcCtD
Methsuximide—Dermatitis—Vinorelbine—lung cancer	0.000854	0.00194	CcSEcCtD
Methsuximide—Headache—Vinorelbine—lung cancer	0.000849	0.00193	CcSEcCtD
Methsuximide—Leukopenia—Docetaxel—lung cancer	0.000848	0.00193	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—lung cancer	0.00084	0.00191	CcSEcCtD
Methsuximide—Feeling abnormal—Cisplatin—lung cancer	0.000836	0.0019	CcSEcCtD
Methsuximide—Haematuria—Methotrexate—lung cancer	0.000833	0.0019	CcSEcCtD
Methsuximide—Somnolence—Etoposide—lung cancer	0.000827	0.00188	CcSEcCtD
Methsuximide—Insomnia—Paclitaxel—lung cancer	0.000825	0.00188	CcSEcCtD
Methsuximide—Phenobarbital—CYP2E1—lung cancer	0.000819	0.059	CrCbGaD
Methsuximide—Somnolence—Paclitaxel—lung cancer	0.00081	0.00185	CcSEcCtD
Methsuximide—Phenobarbital—CYP1A1—lung cancer	0.000808	0.0582	CrCbGaD
Methsuximide—Decreased appetite—Etoposide—lung cancer	0.000808	0.00184	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—lung cancer	0.000805	0.00183	CcSEcCtD
Methsuximide—Nausea—Vinorelbine—lung cancer	0.000805	0.00183	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—lung cancer	0.000803	0.00183	CcSEcCtD
Methsuximide—Constipation—Etoposide—lung cancer	0.000795	0.00181	CcSEcCtD
Methsuximide—Decreased appetite—Paclitaxel—lung cancer	0.000793	0.0018	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000787	0.00179	CcSEcCtD
Methsuximide—Constipation—Paclitaxel—lung cancer	0.00078	0.00177	CcSEcCtD
Methsuximide—Confusional state—Docetaxel—lung cancer	0.000779	0.00177	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—lung cancer	0.000767	0.00175	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—lung cancer	0.000766	0.00174	CcSEcCtD
Methsuximide—Diarrhoea—Irinotecan—lung cancer	0.000765	0.00174	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—SOX2—lung cancer	0.000763	0.00184	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Etoposide—lung cancer	0.00076	0.00173	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—lung cancer	0.000756	0.00172	CcSEcCtD
Methsuximide—Feeling abnormal—Paclitaxel—lung cancer	0.000751	0.00171	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.00075	0.00171	CcSEcCtD
Methsuximide—Gastrointestinal pain—Paclitaxel—lung cancer	0.000746	0.0017	CcSEcCtD
Methsuximide—Diarrhoea—Gemcitabine—lung cancer	0.000745	0.0017	CcSEcCtD
Methsuximide—Erythema multiforme—Methotrexate—lung cancer	0.000741	0.00169	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—NCOA3—lung cancer	0.000741	0.00178	CbGpPWpGaD
Methsuximide—Dizziness—Irinotecan—lung cancer	0.000739	0.00168	CcSEcCtD
Methsuximide—Urticaria—Etoposide—lung cancer	0.000739	0.00168	CcSEcCtD
Methsuximide—Anorexia—Docetaxel—lung cancer	0.000737	0.00168	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—lung cancer	0.000735	0.00167	CcSEcCtD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000734	0.00177	CbGpPWpGaD
Methsuximide—Ketazolam—ALB—lung cancer	0.000729	0.0525	CrCbGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000725	0.00175	CbGpPWpGaD
Methsuximide—Urticaria—Paclitaxel—lung cancer	0.000724	0.00165	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—lung cancer	0.000721	0.00164	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—NCAM1—lung cancer	0.000721	0.00174	CbGpPWpGaD
Methsuximide—Abdominal pain—Paclitaxel—lung cancer	0.000721	0.00164	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—NCOA3—lung cancer	0.000718	0.00173	CbGpPWpGaD
Methsuximide—Vomiting—Irinotecan—lung cancer	0.000711	0.00162	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—FGFR1—lung cancer	0.00071	0.00171	CbGpPWpGaD
Methsuximide—Rash—Irinotecan—lung cancer	0.000705	0.0016	CcSEcCtD
Methsuximide—Dermatitis—Irinotecan—lung cancer	0.000704	0.0016	CcSEcCtD
Methsuximide—Headache—Irinotecan—lung cancer	0.0007	0.00159	CcSEcCtD
Methsuximide—Insomnia—Docetaxel—lung cancer	0.000699	0.00159	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—NCAM1—lung cancer	0.000698	0.00168	CbGpPWpGaD
Methsuximide—Ketazolam—ABCB1—lung cancer	0.000695	0.0501	CrCbGaD
Methsuximide—Diarrhoea—Cisplatin—lung cancer	0.000694	0.00158	CcSEcCtD
Methsuximide—Vomiting—Gemcitabine—lung cancer	0.000692	0.00158	CcSEcCtD
Methsuximide—Somnolence—Docetaxel—lung cancer	0.000687	0.00156	CcSEcCtD
Methsuximide—Rash—Gemcitabine—lung cancer	0.000687	0.00156	CcSEcCtD
Methsuximide—Dermatitis—Gemcitabine—lung cancer	0.000686	0.00156	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—lung cancer	0.000685	0.00165	CbGpPWpGaD
Methsuximide—Headache—Gemcitabine—lung cancer	0.000682	0.00155	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK3—lung cancer	0.000682	0.00164	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—FOXO3—lung cancer	0.000672	0.00162	CbGpPWpGaD
Methsuximide—Decreased appetite—Docetaxel—lung cancer	0.000672	0.00153	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—ITGB1—lung cancer	0.000669	0.00161	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KDR—lung cancer	0.000669	0.00161	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Docetaxel—lung cancer	0.000667	0.00152	CcSEcCtD
Methsuximide—Nausea—Irinotecan—lung cancer	0.000664	0.00151	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—lung cancer	0.000663	0.0016	CbGpPWpGaD
Methsuximide—Constipation—Docetaxel—lung cancer	0.000661	0.0015	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—lung cancer	0.000655	0.00158	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—lung cancer	0.000655	0.00158	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ITGB1—lung cancer	0.000648	0.00156	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ITGB1—lung cancer	0.000648	0.00156	CbGpPWpGaD
Methsuximide—Nausea—Gemcitabine—lung cancer	0.000647	0.00147	CcSEcCtD
Methsuximide—Vomiting—Cisplatin—lung cancer	0.000645	0.00147	CcSEcCtD
Methsuximide—Vision blurred—Methotrexate—lung cancer	0.000643	0.00146	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—lung cancer	0.000642	0.00146	CcSEcCtD
Methsuximide—Rash—Cisplatin—lung cancer	0.00064	0.00146	CcSEcCtD
Methsuximide—Dermatitis—Cisplatin—lung cancer	0.000639	0.00146	CcSEcCtD
Methsuximide—Pethidine—ALB—lung cancer	0.000637	0.0459	CrCbGaD
Methsuximide—Feeling abnormal—Docetaxel—lung cancer	0.000637	0.00145	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—lung cancer	0.000636	0.00145	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—IL6—lung cancer	0.000635	0.00153	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Docetaxel—lung cancer	0.000632	0.00144	CcSEcCtD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.000624	0.0015	CbGpPWpGaD
Methsuximide—Diarrhoea—Paclitaxel—lung cancer	0.000624	0.00142	CcSEcCtD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.000616	0.00148	CbGpPWpGaD
Methsuximide—Dizziness—Etoposide—lung cancer	0.000615	0.0014	CcSEcCtD
Methsuximide—Abdominal pain—Docetaxel—lung cancer	0.000611	0.00139	CcSEcCtD
Methsuximide—Leukopenia—Methotrexate—lung cancer	0.000611	0.00139	CcSEcCtD
Methsuximide—Dizziness—Paclitaxel—lung cancer	0.000603	0.00137	CcSEcCtD
Methsuximide—Nausea—Cisplatin—lung cancer	0.000603	0.00137	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—CNDP2—lung cancer	0.000602	0.00145	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM2—lung cancer	0.000602	0.00145	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HES1—lung cancer	0.000596	0.00144	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000595	0.00143	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM2—lung cancer	0.000594	0.00143	CbGpPWpGaD
Methsuximide—Vomiting—Etoposide—lung cancer	0.000591	0.00135	CcSEcCtD
Methsuximide—Rash—Etoposide—lung cancer	0.000586	0.00133	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—lung cancer	0.000586	0.00133	CcSEcCtD
Methsuximide—Headache—Etoposide—lung cancer	0.000583	0.00133	CcSEcCtD
Methsuximide—Tension—Doxorubicin—lung cancer	0.00058	0.00132	CcSEcCtD
Methsuximide—Vomiting—Paclitaxel—lung cancer	0.00058	0.00132	CcSEcCtD
Methsuximide—Rash—Paclitaxel—lung cancer	0.000575	0.00131	CcSEcCtD
Methsuximide—Dermatitis—Paclitaxel—lung cancer	0.000574	0.00131	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—lung cancer	0.000574	0.00131	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—IL6R—lung cancer	0.000572	0.00138	CbGpPWpGaD
Methsuximide—Headache—Paclitaxel—lung cancer	0.000571	0.0013	CcSEcCtD
Methsuximide—Confusional state—Methotrexate—lung cancer	0.000562	0.00128	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—lung cancer	0.000557	0.00127	CcSEcCtD
Methsuximide—Nausea—Etoposide—lung cancer	0.000552	0.00126	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—MMP2—lung cancer	0.000546	0.00132	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAP2K1—lung cancer	0.000546	0.00131	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP2A7—lung cancer	0.000544	0.00131	CbGpPWpGaD
Methsuximide—Nausea—Paclitaxel—lung cancer	0.000542	0.00123	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP2A7—lung cancer	0.000537	0.00129	CbGpPWpGaD
Methsuximide—Anorexia—Methotrexate—lung cancer	0.000531	0.00121	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—lung cancer	0.000529	0.0012	CcSEcCtD
Methsuximide—Diarrhoea—Docetaxel—lung cancer	0.000529	0.0012	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—FGFR1—lung cancer	0.000524	0.00126	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—CYP1A1—lung cancer	0.000519	0.00125	CbGpPWpGaD
Methsuximide—Dizziness—Docetaxel—lung cancer	0.000511	0.00116	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—FGFR1—lung cancer	0.000507	0.00122	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—FGFR1—lung cancer	0.000507	0.00122	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	0.000506	0.00122	CbGpPWpGaD
Methsuximide—Insomnia—Methotrexate—lung cancer	0.000504	0.00115	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—FOXO3—lung cancer	0.000496	0.00119	CbGpPWpGaD
Methsuximide—Somnolence—Methotrexate—lung cancer	0.000495	0.00113	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—KDR—lung cancer	0.000493	0.00119	CbGpPWpGaD
Methsuximide—Clobazam—ABCB1—lung cancer	0.000492	0.0354	CrCbGaD
Methsuximide—Vomiting—Docetaxel—lung cancer	0.000491	0.00112	CcSEcCtD
Methsuximide—Rash—Docetaxel—lung cancer	0.000487	0.00111	CcSEcCtD
Methsuximide—Dermatitis—Docetaxel—lung cancer	0.000487	0.00111	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—lung cancer	0.000486	0.00111	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTA3—lung cancer	0.000485	0.00117	CbGpPWpGaD
Methsuximide—Decreased appetite—Methotrexate—lung cancer	0.000484	0.0011	CcSEcCtD
Methsuximide—Headache—Docetaxel—lung cancer	0.000484	0.0011	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—RAF1—lung cancer	0.000484	0.00117	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MET—lung cancer	0.000483	0.00116	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Methotrexate—lung cancer	0.000481	0.00109	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—FOXO3—lung cancer	0.00048	0.00116	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—ERBB2—lung cancer	0.000479	0.00115	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTA3—lung cancer	0.000479	0.00115	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KDR—lung cancer	0.000478	0.00115	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ITGB1—lung cancer	0.000478	0.00115	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KDR—lung cancer	0.000478	0.00115	CbGpPWpGaD
Methsuximide—Phenytoin—ALB—lung cancer	0.00047	0.0338	CrCbGaD
Methsuximide—CACNA1H—Axon guidance—MET—lung cancer	0.000468	0.00113	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—lung cancer	0.000467	0.00113	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ITGB1—lung cancer	0.000462	0.00111	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—AKT1—lung cancer	0.00046	0.00111	CbGpPWpGaD
Methsuximide—Anorexia—Doxorubicin—lung cancer	0.00046	0.00105	CcSEcCtD
Methsuximide—Nausea—Docetaxel—lung cancer	0.000459	0.00105	CcSEcCtD
Methsuximide—Feeling abnormal—Methotrexate—lung cancer	0.000459	0.00104	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methotrexate—lung cancer	0.000455	0.00104	CcSEcCtD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000449	0.00108	CbGpPWpGaD
Methsuximide—Phenytoin—ABCB1—lung cancer	0.000448	0.0323	CrCbGaD
Methsuximide—CYP2C19—Biological oxidations—GSTA4—lung cancer	0.000444	0.00107	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000443	0.00107	CbGpPWpGaD
Methsuximide—Urticaria—Methotrexate—lung cancer	0.000442	0.00101	CcSEcCtD
Methsuximide—Abdominal pain—Methotrexate—lung cancer	0.00044	0.001	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—HES1—lung cancer	0.000439	0.00106	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTA4—lung cancer	0.000438	0.00105	CbGpPWpGaD
Methsuximide—Insomnia—Doxorubicin—lung cancer	0.000436	0.000993	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTA2—lung cancer	0.000433	0.00104	CbGpPWpGaD
Methsuximide—Phenobarbital—ABCB1—lung cancer	0.00043	0.0309	CrCbGaD
Methsuximide—Somnolence—Doxorubicin—lung cancer	0.000429	0.000976	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—HES1—lung cancer	0.000425	0.00102	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6R—lung cancer	0.000422	0.00102	CbGpPWpGaD
Methsuximide—Decreased appetite—Doxorubicin—lung cancer	0.000419	0.000954	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTA1—lung cancer	0.000417	0.00101	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000416	0.000948	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—lung cancer	0.000412	0.000939	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—MMP9—lung cancer	0.000411	0.000989	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6R—lung cancer	0.000409	0.000984	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6R—lung cancer	0.000408	0.000984	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CREBBP—lung cancer	0.000408	0.000982	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP2—lung cancer	0.000403	0.00097	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAP2K1—lung cancer	0.000402	0.000969	CbGpPWpGaD
Methsuximide—Feeling abnormal—Doxorubicin—lung cancer	0.000397	0.000905	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—lung cancer	0.000394	0.000898	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—AKR1C1—lung cancer	0.000394	0.000949	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP2—lung cancer	0.00039	0.000939	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP2—lung cancer	0.00039	0.000939	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAP2K1—lung cancer	0.00039	0.000938	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAP2K1—lung cancer	0.000389	0.000938	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—UGT1A1—lung cancer	0.000388	0.000934	CbGpPWpGaD
Methsuximide—Urticaria—Doxorubicin—lung cancer	0.000383	0.000872	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—UGT1A1—lung cancer	0.000383	0.000922	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.000382	0.000919	CbGpPWpGaD
Methsuximide—Abdominal pain—Doxorubicin—lung cancer	0.000381	0.000868	CcSEcCtD
Methsuximide—Diarrhoea—Methotrexate—lung cancer	0.000381	0.000868	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—SRC—lung cancer	0.000379	0.000912	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—FGFR1—lung cancer	0.000374	0.0009	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—VEGFA—lung cancer	0.000369	0.000888	CbGpPWpGaD
Methsuximide—Dizziness—Methotrexate—lung cancer	0.000368	0.000839	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—NRAS—lung cancer	0.000364	0.000877	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000364	0.000876	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—FGFR1—lung cancer	0.000362	0.000872	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—RAF1—lung cancer	0.000357	0.000859	CbGpPWpGaD
Methsuximide—Vomiting—Methotrexate—lung cancer	0.000354	0.000806	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—ERBB2—lung cancer	0.000353	0.00085	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KDR—lung cancer	0.000352	0.000848	CbGpPWpGaD
Methsuximide—Rash—Methotrexate—lung cancer	0.000351	0.0008	CcSEcCtD
Methsuximide—Dermatitis—Methotrexate—lung cancer	0.000351	0.000799	CcSEcCtD
Methsuximide—Headache—Methotrexate—lung cancer	0.000349	0.000794	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—MAPK3—lung cancer	0.000349	0.00084	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—RAF1—lung cancer	0.000345	0.000832	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—RAF1—lung cancer	0.000345	0.000832	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MET—lung cancer	0.000345	0.00083	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ERBB2—lung cancer	0.000342	0.000823	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—lung cancer	0.000342	0.000823	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KDR—lung cancer	0.000341	0.000821	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000334	0.000806	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—lung cancer	0.000334	0.000804	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EGFR—lung cancer	0.000332	0.000799	CbGpPWpGaD
Methsuximide—Nausea—Methotrexate—lung cancer	0.000331	0.000753	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—lung cancer	0.00033	0.000751	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—HPGDS—lung cancer	0.00033	0.000794	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTT1—lung cancer	0.00032	0.000771	CbGpPWpGaD
Methsuximide—Dizziness—Doxorubicin—lung cancer	0.000319	0.000726	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—CYP2A6—lung cancer	0.000316	0.000762	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GCLC—lung cancer	0.000316	0.000762	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KRAS—lung cancer	0.000313	0.000755	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS2—lung cancer	0.000309	0.000743	CbGpPWpGaD
Methsuximide—Vomiting—Doxorubicin—lung cancer	0.000307	0.000698	CcSEcCtD
Methsuximide—Rash—Doxorubicin—lung cancer	0.000304	0.000692	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—lung cancer	0.000304	0.000692	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—MMP9—lung cancer	0.000303	0.000729	CbGpPWpGaD
Methsuximide—Headache—Doxorubicin—lung cancer	0.000302	0.000688	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—IL6R—lung cancer	0.000301	0.000725	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CREBBP—lung cancer	0.000301	0.000724	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—lung cancer	0.000293	0.000706	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—lung cancer	0.000293	0.000706	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6R—lung cancer	0.000292	0.000702	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CREBBP—lung cancer	0.000291	0.000701	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	0.000289	0.000696	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP2—lung cancer	0.000287	0.000692	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAP2K1—lung cancer	0.000287	0.000691	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—lung cancer	0.000286	0.000652	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—SRC—lung cancer	0.000279	0.000672	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP2—lung cancer	0.000278	0.00067	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAP2K1—lung cancer	0.000278	0.000669	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EP300—lung cancer	0.000278	0.000669	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—lung cancer	0.000272	0.000655	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—lung cancer	0.000271	0.000653	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—SRC—lung cancer	0.00027	0.000651	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SRC—lung cancer	0.00027	0.000651	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP2E1—lung cancer	0.000269	0.000648	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—lung cancer	0.000268	0.000647	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—lung cancer	0.000266	0.000642	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP2E1—lung cancer	0.000265	0.000639	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—lung cancer	0.000263	0.000634	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—lung cancer	0.000263	0.000634	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—STAT3—lung cancer	0.00026	0.000627	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—lung cancer	0.00026	0.000626	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—lung cancer	0.00026	0.000626	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK3—lung cancer	0.000257	0.000619	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—IL6—lung cancer	0.000255	0.000614	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—RAF1—lung cancer	0.000255	0.000613	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—lung cancer	0.000252	0.000606	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK3—lung cancer	0.000249	0.0006	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK3—lung cancer	0.000249	0.000599	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—RAF1—lung cancer	0.000247	0.000594	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EGFR—lung cancer	0.000245	0.000589	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—lung cancer	0.000244	0.000587	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—lung cancer	0.000237	0.000571	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—lung cancer	0.000237	0.00057	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—lung cancer	0.000231	0.000557	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	0.000225	0.000542	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—lung cancer	0.000224	0.000539	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—lung cancer	0.000224	0.000539	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTP1—lung cancer	0.000222	0.000534	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTP1—lung cancer	0.000219	0.000527	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—lung cancer	0.000216	0.00052	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—lung cancer	0.000209	0.000504	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EP300—lung cancer	0.000205	0.000493	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM1—lung cancer	0.000204	0.000491	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM1—lung cancer	0.000201	0.000484	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SRC—lung cancer	0.000199	0.00048	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EP300—lung cancer	0.000198	0.000478	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—lung cancer	0.000196	0.000473	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—lung cancer	0.000194	0.000467	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1A1—lung cancer	0.000193	0.000465	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SRC—lung cancer	0.000193	0.000465	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—STAT3—lung cancer	0.000192	0.000463	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRAS—lung cancer	0.000192	0.000461	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1A1—lung cancer	0.000191	0.000459	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—lung cancer	0.00019	0.000458	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—lung cancer	0.00019	0.000458	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6—lung cancer	0.000188	0.000453	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—lung cancer	0.000188	0.000452	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—STAT3—lung cancer	0.000186	0.000448	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—lung cancer	0.000186	0.000447	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK3—lung cancer	0.000183	0.000442	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6—lung cancer	0.000182	0.000438	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6—lung cancer	0.000182	0.000438	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK3—lung cancer	0.000178	0.000428	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—lung cancer	0.000175	0.00042	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AZIN2—lung cancer	0.00017	0.000409	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—COL4A3BP—lung cancer	0.00017	0.000409	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—lung cancer	0.000169	0.000407	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—lung cancer	0.000168	0.000404	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—lung cancer	0.000165	0.000397	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—lung cancer	0.00016	0.000385	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	0.000158	0.000382	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	0.000153	0.00037	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ATP5H—lung cancer	0.000144	0.000348	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—POMC—lung cancer	0.000144	0.000347	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—lung cancer	0.00014	0.000338	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—lung cancer	0.000136	0.000327	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6—lung cancer	0.000134	0.000323	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	0.000133	0.00032	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6—lung cancer	0.00013	0.000313	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PLBD1—lung cancer	0.000129	0.00031	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	0.000127	0.000305	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—lung cancer	0.000124	0.000298	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—lung cancer	0.00012	0.000289	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSD17B10—lung cancer	0.000118	0.000284	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CKB—lung cancer	0.00011	0.000264	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM2—lung cancer	0.000103	0.000248	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CNDP2—lung cancer	0.000103	0.000248	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTMR3—lung cancer	0.0001	0.000241	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PGAM1—lung cancer	9.76e-05	0.000235	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP2A7—lung cancer	9.31e-05	0.000224	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SDC4—lung cancer	9.11e-05	0.000219	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RRM1—lung cancer	8.3e-05	0.0002	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA3—lung cancer	8.3e-05	0.0002	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—B4GALT5—lung cancer	7.8e-05	0.000188	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA4—lung cancer	7.59e-05	0.000183	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	7.42e-05	0.000179	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA2—lung cancer	7.4e-05	0.000178	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA1—lung cancer	7.14e-05	0.000172	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCC3—lung cancer	7.06e-05	0.00017	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKR1C1—lung cancer	6.83e-05	0.000165	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UGT1A1—lung cancer	6.63e-05	0.00016	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GNG11—lung cancer	6.4e-05	0.000154	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—lung cancer	6.36e-05	0.000153	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALDOA—lung cancer	6.09e-05	0.000147	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOA3—lung cancer	5.91e-05	0.000142	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	5.81e-05	0.00014	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCG2—lung cancer	5.75e-05	0.000139	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ADCY1—lung cancer	5.75e-05	0.000139	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO2—lung cancer	5.64e-05	0.000136	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HPGDS—lung cancer	5.64e-05	0.000136	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPP2R1B—lung cancer	5.61e-05	0.000135	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—lung cancer	5.53e-05	0.000133	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTT1—lung cancer	5.47e-05	0.000132	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP2A6—lung cancer	5.41e-05	0.00013	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GCLC—lung cancer	5.41e-05	0.00013	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	5.39e-05	0.00013	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO1—lung cancer	5.13e-05	0.000123	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	5.11e-05	0.000123	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	5.04e-05	0.000121	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP2E1—lung cancer	4.6e-05	0.000111	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NQO1—lung cancer	4.55e-05	0.00011	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.45e-05	0.000107	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.41e-05	0.000106	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—STK11—lung cancer	4.1e-05	9.87e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.85e-05	9.27e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTP1—lung cancer	3.79e-05	9.13e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CAT—lung cancer	3.69e-05	8.89e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.67e-05	8.84e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCB1—lung cancer	3.59e-05	8.65e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMS—lung cancer	3.53e-05	8.49e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM1—lung cancer	3.49e-05	8.39e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1A1—lung cancer	3.3e-05	7.96e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ERCC2—lung cancer	3.28e-05	7.89e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—APOA1—lung cancer	2.83e-05	6.83e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.71e-05	6.54e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CG—lung cancer	2.59e-05	6.23e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—POMC—lung cancer	2.46e-05	5.93e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CREBBP—lung cancer	2.4e-05	5.78e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CD—lung cancer	2.27e-05	5.48e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALB—lung cancer	2.25e-05	5.41e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CB—lung cancer	1.98e-05	4.78e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS2—lung cancer	1.96e-05	4.73e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—lung cancer	1.71e-05	4.13e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—EP300—lung cancer	1.63e-05	3.94e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—lung cancer	1.21e-05	2.91e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—lung cancer	9.87e-06	2.38e-05	CbGpPWpGaD
